Vol. 55 No. 1 (2016): Acta Oncologica

Articles

• Prognostic factors for the feasibility of chemotherapy and the Geriatric Prognostic Index (GPI) as risk profile for mortality before chemotherapy in the elderly

  Ab A. Aaldriks, Ed Maartense, Hans J. W. R. Nortier, Lydia G. M. van der Geest, Saskia le Cessie, Bea C. Tanis, Johanneke E. A. Portielje, Paula Ypma, Erik J. Giltay

  15-23

  Published: 2016-01-02

  • PDF

• Late urinary toxicity modeling after stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer

  Thomas P. Kole, Michael Tong, Binbin Wu, Siyuan Lei, Olusola Obayomi-Davies, Leonard N. Chen, Simeng Suy, Anatoly Dritschilo, Ellen Yorke, Sean P. Collins

  52-58

  Published: 2016-01-02

  • PDF
  • Supplemental Material

• Familial Waldenstrom’s macroglobulinemia and relation to immune defects, autoimmune diseases, and haematological malignancies – A population-based study from northern Sweden

  Lena Brandefors, Eva Kimby, Kristina Lundqvist, Beatrice Melin, Jack Lindh

  91-98

  Published: 2016-01-02

  • PDF

• BRAF V600E mutation: A treatable driver mutation in pleomorphic xanthoastrocytoma (PXA)

  Silvia Hofer, Grégoire Berthod, Christian Riklin, Elisabeth Rushing, Jonas Feilchenfeldt

  122-123

  Published: 2016-01-02

  • PDF

• It’s time to move forward in geriatric oncology

  Trine Lembrecht Jørgensen, Per Pfeiffer

  1-2

  Published: 2016-01-02

  • PDF

• Increased risk of male cancer and identification of a potential prostate cancer cluster region in BRCA2

  Henriette Roed Nielsen, Janne Petersen, Christina Therkildsen, Anne-Bine Skytte, Mef Nilbert

  38-44

  Published: 2016-01-02

  • PDF

• CHOP-like-14 compared to CHOP-like-21 for patients with aggressive lymphoma – a meta-analysis of randomized controlled trials

  Liat Vidal, Ofer Shpilberg, Ronit Gurion, Ina Monsef, Pia Raanani, Ron Ram, Anat Gafter-Gvili

  77-84

  Published: 2016-01-02

  • PDF

• Very low rate of circulating tumour cells (CTCs) in patients with PSA recurrence after radical prostatectomy referred to salvage radiotherapy

  Adalsteinn Gunnlaugsson, Per Nilsson, Elisabeth Kjellén, René Blom

  113-115

  Published: 2016-01-02

  • PDF

• Quality assessment of prostate cancer reports to the Danish Cancer Registry

  Inga Jóna Ingimarsdóttir, Ea Rusch, Gerda Engholm, Hans H. Storm, Klaus Brasso

  24-29

  Published: 2016-01-02

  • PDF

• Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial

  Ivan Jambor, Anna Kuisma, Susan Ramadan, Riikka Huovinen, Minna Sandell, Sami Kajander, Jukka Kemppainen, Esa Kauppila, Joakim Auren, Harri Merisaari, Jani Saunavaara, Tommi Noponen, Heikki Minn, Hannu J. Aronen, Marko Seppänen

  59-67

  Published: 2016-01-02

  • PDF

• Dose-volume factors correlating with trismus following chemoradiation for head and neck cancer

  Shyam D. Rao, Ziad H. Saleh, Jeremy Setton, Moses Tam, Sean M. McBride, Nadeem Riaz, Joseph O. Deasy, Nancy Y. Lee

  99-104

  Published: 2016-01-02

  • PDF

• Diagnosis and treatment of bronchopulmonary neuroendocrine tumours: State of the art

  Elizaveta Mitkina Tabaksblat, Seppo W. Langer, Ulrich Knigge, Henning Grønbæk, Jann Mortensen, René Horsleben Petersen, Birgitte Hartnack Federspiel, Morten Ladekarl

  3-14

  Published: 2016-01-02

  • PDF

• Public interest in and acceptability of the prospect of risk-stratified screening for breast and prostate cancer

  Marie Koitsalu, Mirjam A. G. Sprangers, Martin Eklund, Kamila Czene, Per Hall, Henrik Grönberg, Yvonne Brandberg

  45-51

  Published: 2016-01-02

  • PDF
  • Supplemental Material

• Aetiologic heterogeneity in pediatric Hodgkin lymphoma? Evidence from the Nordic countries, 1978–2010

  Lisa Lyngsie Hjalgrim, Klaus Rostgaard, Gerda Engholm, Eero Pukkala, Tom Børge Johannesen, Elínborg Ólafsdóttir, Henrik Hjalgrim

  85-90

  Published: 2016-01-02

  • PDF

• Intensity-modulated and 3D-conformal radiotherapy in hypofractionated prostate cancer treatment using Elekta Beam ModulatorTM micro-MLC: A dosimetric analysis

  Alessandra Carosi, Gianluca Ingrosso, Elisabetta Ponti, Andrea Lancia, Riccardo Santoni

  116-121

  Published: 2016-01-02

  • PDF

• Costs in different states of prostate cancer

  Saku Torvinen, Niilo Färkkilä, Risto P. Roine, Harri Sintonen, Tiina Saarto, Kimmo Taari

  30-37

  Published: 2016-01-02

  • PDF

• The amount of injected 177Lu-octreotate strongly influences biodistribution and dosimetry in C57BL/6N mice

  Emil Schüler, Andreas Österlund, Eva Forssell-Aronsson

  68-76

  Published: 2016-01-02

  • PDF
  • Supplemental Material

• Positive correlation between occlusion rate and nidus size of proton beam treated brain arteriovenous malformations (AVMs)

  Erik Blomquist, Elisabeth Ronne-Engström, Ljubisa Borota, Gyula Gál, Kristina Nilsson, Anders Lewén, Anders Montelius, Erik Grusell, Ulf Isacsson, Per Enblad

  105-112

  Published: 2016-01-02

  • PDF